Banco Santander S.A. lowered its position in Amgen, Inc. (NASDAQ:AMGN) by 32.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,642 shares of the medical research company’s stock after selling 4,145 shares during the quarter. Banco Santander S.A.’s holdings in Amgen were worth $1,679,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Gifford Fong Associates increased its holdings in shares of Amgen by 25.3% in the 2nd quarter. Gifford Fong Associates now owns 67,671 shares of the medical research company’s stock valued at $12,470,000 after acquiring an additional 13,671 shares during the period. Bray Capital Advisors increased its holdings in shares of Amgen by 11.6% in the 2nd quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock valued at $3,626,000 after acquiring an additional 2,045 shares during the period. CHICAGO TRUST Co NA grew its position in Amgen by 2.8% in the 2nd quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock valued at $685,000 after buying an additional 100 shares during the last quarter. Private Advisor Group LLC grew its position in Amgen by 4.0% in the 2nd quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock valued at $7,093,000 after buying an additional 1,494 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Amgen in the 2nd quarter valued at $15,515,000. 76.64% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $193.58, for a total transaction of $387,160.00. Following the sale, the director now directly owns 16,436 shares of the company’s stock, valued at approximately $3,181,680.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO David W. Meline sold 8,737 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $234.36, for a total value of $2,047,603.32. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,162 shares of company stock worth $5,014,590. Corporate insiders own 0.25% of the company’s stock.
NASDAQ AMGN opened at $234.72 on Friday. The stock has a market cap of $139.27 billion, a PE ratio of 16.30, a P/E/G ratio of 2.37 and a beta of 1.09. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. The business has a 50 day moving average price of $215.09 and a two-hundred day moving average price of $193.83. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $235.80.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.13. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business’s revenue was down 2.8% on a year-over-year basis. During the same period in the prior year, the business posted $3.69 EPS. Sell-side analysts anticipate that Amgen, Inc. will post 14.65 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Friday, November 15th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.47%. The ex-dividend date of this dividend is Thursday, November 14th. Amgen’s dividend payout ratio is currently 40.28%.
A number of research firms recently weighed in on AMGN. Bank of America began coverage on shares of Amgen in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price objective on the stock. Credit Suisse Group restated an “outperform” rating and set a $225.00 target price (up from $202.00) on shares of Amgen in a research report on Friday, August 16th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Sanford C. Bernstein assumed coverage on Amgen in a research note on Monday, October 14th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research note on Monday, September 30th. Ten investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Amgen has an average rating of “Buy” and a consensus price target of $221.47.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Google Finance Portfolio Workaround
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.